Zoetis Inc. (ZTS)

NYSE: ZTS · USD

$77.7

-0.53 (-0.7%)· Recorded snapshot

英文原文ZH

翻译期间显示英文原文

此报告尚未翻译。翻译队列赶上后请在几分钟内刷新。

StockMarketAgent Research · Analyzed 2026-10-22

Our latest published analysis: ZTS rated Buy

Zoetis Inc.'s published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$95.5 / share

Potential value

$131 / share

Upside to FV

+19.9%

from $77.7

Moat

8.5/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$32.9B
Revenue (ttm)	9.5B
Net income (ttm)	2.6B
EPS (ttm)	$6.13
Shares out	413.2M
P/E (trailing)	12.7x
P/E (forward)	12.0x
Dividend	$2.12 (2.73%)
Volume	2,035,417
Beta	0.74

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 9.5B
Net income (ttm): 2.6B
EPS (ttm): $6.13
P/E (trailing): 12.7x
P/E (forward): 12.0x
Market cap: $32.9B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$7.78B	$8.08B	$8.54B	$9.26B	$9.47B	+5.0%
Gross profit	$5.31B	$5.48B	$5.83B	$6.40B	$6.67B	+5.9%
Operating income	$2.72B	$2.89B	$3.19B	$3.38B	$3.58B	+7.1%
Net income	$2.04B	$2.11B	$2.34B	$2.49B	$2.67B	+7.0%
EPS (diluted)	$4.27	$4.49	$5.07	$5.47	$6.02	+9.0%
EBITDA	$3.17B	$3.36B	$3.69B	$3.87B	$4.07B	+6.4%
R&D	$508.0M	$539.0M	$614.0M	$686.0M	$698.0M	+8.3%
SG&A	$2.00B	$2.01B	$2.15B	$2.32B	$2.38B	+4.4%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	5T	39.4x	10.8x	101.6%	+6.1%	+28.5%	卖出
ABNB	Airbnb, Inc.	97.8B	37.5x	7.4x	16.8%	+24.4%	+28.5%	卖出
ADBE	Adobe Inc.	97.1B	13.9x	3.7x	57.2%	+11.5%	-30.7%	强力买入
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	卖出
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	减持
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	减持

Base and Bull scenarios

Bull20%

Price target

$131.22

+64.8% from spot

In the Bull scenario, veterinary clinic foot traffic rebounds swiftly while international uptake of novel pain monoclonal antibodies Lenivia and Portela exceeds expectations. Dermatology pricing remains resilient as veterinary switching barriers limit competitor share gains. Operating margins expand through operating leverage, and active share repurchases drive sustained compound EPS growth annually.

Accelerated revenue compound growth driven by international expansion and pain biologics
Operating margins expand significantly through operating leverage by FY2030
Diluted share count decreases steadily via ongoing share repurchases
Global blockbusters Lenivia and Portela achieve rapid commercial adoption

Base55%

Price target

$95.48

+19.9% from spot

In the Base scenario, FY2026 revenue reflects the reset guidance range ($9.12B to $9.32B) with EPS of $6.21, before accelerating to 2.51% revenue growth and $6.52 EPS in FY2027. Operating margins normalize to 38.5% by FY2030, while free cash flow generation enables sustained share count reduction of ~1% per year.

FY2026 revenue of $9,253M and EPS of $6.21
FY2027 revenue of $9,485M and EPS of $6.52
Operating margin expands from 37.0% in FY2026 to 38.5% in FY2030
Terminal growth rate of 2.5% and cost of equity of 8.67%

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($95.48). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	2.0%	2.3%	2.5%	2.8%	3.0%
7.7%	$104	$107	$110	$114	$117
8.2%	$97.3	$99.5	$102	$105	$108
8.7%	$91.6	$93.4	$95.5	$97.7	$100
9.2%	$86.7	$88.2	$89.9	$91.7	$93.8
9.7%	$82.4	$83.7	$85.1	$86.7	$88.3

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E12

P25 n/aP50 n/aP75 n/a

Trailing P/E13.2

P25 n/aP50 n/aP75 n/a

ROE64.9

P25 n/aP50 n/aP75 n/a

ROIC27.3

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ZTS indicators

Market & fundamental data

Available fields

284

Groups with data

Currency

USD

Showing 284 of 284 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001555280
Company name	Zoetis Inc.
Country	United States
Country code	US
CUSIP number	98978V103
Earnings date	2026-11-05
Earnings time	bmo
Employees	14,500
Employees change	700
Employees growth	5.07%
Enterprise value	$39.7B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1952
In index	SP500
Industry	Drug Manufacturers - Specialty & Generic
IPO date	2013-02-01
Is primary listing	Yes
Is SPAC	No
ISIN number	US98978V1035
Last 10-K release date	2026-02-12
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$32.1B
Market cap category	Large-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$77.70
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	ZTS
U.S. state	New Jersey
Website	https://www.zoetis.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	11.81x
Average P/E ratio (10Y)	35.79x
Average P/E ratio (3Y)	28.15x
Average P/E ratio (5Y)	33.08x
Earnings yield	7.89%
EV/Earnings	15.11x
EV/EBIT	10.98x
EV/EBITDA	9.8x
EV/FCF	17.2x
EV/Sales	4.18x
FCF / EV yield	5.81%
FCF yield	7.18%
Forward EV/Sales	4.31x
Forward P/E	12.59x
Forward P/S	3.49x
Graham number	32.37619
Graham upside	-58.53%
Industry forward P/E	13.87x
Industry P/E	173.94x
Lynch fair value	$40.91
Lynch upside	-47.6%
P/(FCF - SBC) ratio	14.53x
P/(OCF - SBC) ratio	11.75x
P/B ratio	10.29x
P/E ratio	12.68x
P/FCF ratio	13.93x
P/OCF ratio	11.36x
P/S ratio	3.39x
PEG ratio	1.21x
Price/EBITDA ratio	7.93x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	38.11%
EBITDA margin	42.69%
Effective tax rate	20.07%
FCF margin	24.31%
Gross margin	71.74%
Operating margin	38.11%
Pretax margin	34.64%
Profit margin	27.69%
Profit per employee	$181,862
Profitable quarters	44
Profitable years	16
Revenue per employee	$656,897
ROA	15.35%
ROA (5Y)	13.76%
ROCE	27.89%
ROE	64.91%
ROE (5Y)	52.61%
ROIC	27.28%
ROIC (5Y)	28.07%
SBC / revenue	1%
Tax / revenue	6.95%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	6.23%
EPS growth (Q)	1.23%
EPS growth (QoQ)	16.2%
EPS growth 10Y	16.92%
EPS growth 3Y	8.9%
EPS growth 5Y	8.97%
EPS growth quarters	8
EPS growth years	10
FCF growth	2.07%
FCF growth (Q)	17.21%
FCF growth (QoQ)	84.88%
FCF growth 3Y	21.7%
FCF growth 5Y	6.35%
Gross profit growth	2.12%
Gross profit growth (Q)	-0.77%
Gross profit growth 3Y	5.77%
Gross profit growth 5Y	5.76%
Net income growth	1.78%
Net income growth (Q)	-4.82%
Net income growth (QoQ)	14.98%
Net income growth 3Y	6.02%
Net income growth 5Y	6.67%
Net income growth years	10
OCF growth	-4.57%
OCF growth (Q)	8.26%
OCF growth (QoQ)	63.34%
OCF growth 10Y	15.54%
OCF growth 3Y	12.42%
OCF growth 5Y	5.62%
Operating income growth	3.15%
Operating income growth (Q)	-0.3%
Operating income growth 3Y	6.76%
Operating income growth 5Y	6.26%
Revenue growth	1.58%
Revenue growth (Q)	-0.24%
Revenue growth (QoQ)	9.11%
Revenue growth 10Y	6.96%
Revenue growth 3Y	5.03%
Revenue growth 5Y	5.14%
Revenue growth years	10

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-524M
Depreciation and amortization	$436M
EBIT	$3.6B
EBITDA	$4.1B
EPS	$6.13
FCF per share	$5.60
Financing cash flow	$-2.3B
Free cash flow	$2.3B
Free cash flow minus SBC	$2.2B
Gross profit	$6.8B
Income taxes	$662M
Investing cash flow	$-720M
Net borrowing	$2.3B
Net cash flow	$-167M
Net income	$2.6B
Operating cash flow minus SBC	$2.7B
Operating income	$3.6B
Revenue	$9.5B
Stock-based compensation	$95M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	5.87
Book value per share	$7.60
Debt / EBITDA	2.21
Debt / equity	2.94
Debt / FCF	4
Goodwill	$2.8B
Interest coverage	15.25
Long-term assets	$8.7B
Long-term liabilities	$9.9B
Net cash (debt)	$-7.6B
Net cash / market cap	-23.49%
Net debt / EBITDA	1.86
Net debt / equity	2.41
Net debt / FCF	3.27
Piotroski F-Score	6
Property, plant and equipment	$4B
Shareholders' equity	$3.1B
Tangible book value	$-541M
Tangible book value per share	$-1.31
Total assets	$15.1B
Total cash	$1.7B
Total debt	$9.3B
Total liabilities	$11.9B
WACC	6.92%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.64
Current assets	$6.4B
Current liabilities	$2.1B
Current ratio	3.08
Inventory turnover	1.07
Net working capital	$2.6B
Quick ratio	1.58
Working capital	$4.3B
Working capital turnover	2.78

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	4.22%
Dividend growth	6%
Dividend growth (10Y)	18.76%
Dividend growth (3Y)	12.22%
Dividend growth (5Y)	16.22%
Dividend growth years	12
Dividend payment date	2026-12-01
Dividend payment years	14
Dividend payout frequency	Quarterly
Dividend per share	$2.12
Dividend yield	2.73%
Ex-dividend date	2026-10-30
FCF payout ratio	37.83%
Last dividend	$0.53
Payout ratio	34.59%
Shareholder yield	6.94%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	59.31%
10Y return CAGR	5.69%
10Y total return	73.91%
150-day SMA	$84.05
1D price change	-0.68%
1M price change	9.35%
1M total return	9.35%
1W price change	-2.42%
1W total return	-2.42%
1Y price change	-47.34%
1Y return CAGR	-46.35%
1Y total return	-46.32%
20-day SMA	$76.16
200-day SMA	$93.99
3M price change	1.01%
3M total return	1.01%
3Y price change	-50.21%
3Y return CAGR	-19.64%
3Y total return	-48.12%
50-day SMA	$74.91
50-day SMA vs 200-day SMA	50under200
52-week high	$147.46
52-week high date	2025-10-28
52-week low	$68.77
52-week low date	2026-10-02
5Y price change	-62.93%
5Y return CAGR	-17.08%
5Y total return	-60.79%
6M price change	-34.08%
6M total return	-33.62%
All-time high	$249.27
All-time high date	2021-12-30
All-time low	$28.14
All-time low date	2014-04-15
Average true range (ATR)	$1.88
Average volume	3.8M
Beta (1Y)	0.15
Beta (2Y)	0.34
Beta (5Y)	0.74
Change from 52-week high	-47.31%
Change from 52-week low	12.98%
Change from all-time high	-68.83%
Change from all-time low	176.15%
Change from open	-0.13%
Day's gap	-0.55%
Dollar volume	$158.1M
High price	$78.40
Low price	$77.08
Monthly RSI	30.44
Open price	$77.80
Position in 52-week range	46.59%
Premarket change	-1.3%
Premarket close	$78.23
Premarket price	$77.21
Premarket volume	7.3K
Previous close	$78.23
Price vs 150-day SMA	-7.56%
Price vs 20-day SMA	2.02%
Price vs 200-day SMA	-17.33%
Price vs 50-day SMA	3.72%
Relative volume	0.54
RSI	54.32
Sharpe ratio	-1.52
Sharpe ratio (3Y)	-0.76
Sharpe ratio (5Y)	-0.61
Sortino ratio	-1.64
Sortino ratio (3Y)	-0.78
Sortino ratio (5Y)	-0.61
Volume	2M
Weekly RSI	41.71
YTD price change	-38.25%
YTD total return	-37.28%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	412.4M
Float percentage	99.79%
Shares change (QoQ)	-1.11%
Shares change (YoY)	-4.22%
Shares held by insiders	0.1%
Shares held by institutions	98.49%
Shares outstanding	413.2M
Short % of float	4.47%
Short % of shares	4.46%
Short ratio	4 days

Other indicators

Additional ticker metrics that do not fit the primary research groupings.

Metric	Value
Page views	171

Deeper analysis on ZTS

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this ZTS report

What is the latest published ZTS stock rating?

Zoetis Inc. is shown with Buy in the latest published report, analyzed 2026-10-22. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ZTS analysis?

The full latest published report, analyzed 2026-10-22, lives at /stocks/ZTS/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for ZTS?

The latest published report analyzed 2026-10-22 gives ZTS a fair value of USD 95 and a potential value of USD 131. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the ZTS page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-22). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

BuyZTS · Fair value $95.5+19.9%

Read full analysis →

Zoetis Inc. (ZTS)

Our latest published analysis: ZTS rated Buy

Price

Financial snapshot

Fair-value bridge

Latest news · ZTS

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All ZTS indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Other indicators

Deeper analysis on ZTS

Frequently asked questions

评级历史

Category	Score	Reading
Valuation	7.5
Management	8.5
Balance Sheet	5.0
Profitability	8.5
Revenue Growth	2.5
Risk Assessment	5.5
Competitive Moat	8.5
Earnings Quality	6.0
Capital Efficiency	8.5